Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSURE: Chemoradiotherapy vs Esophagectomy for Superficial Esophageal Squamous Cell Carcinoma
NCT03306901Active, not recruiting
- Sponsor
- Samsung Medical Center
- Start
- Oct 2017
- Primary completion
- Dec 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of fluorouracil and Cisplatin micelle injection (HA132) in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Samsung Medical Center. Started Oct 2017; status: active, not recruiting.
02
Drugs
fluorouracilCisplatin micelle injection (HA132)
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03306901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03306901.